Search results
Results from the WOW.Com Content Network
The LVAD is the most common device applied to a defective heart (it is sufficient in most cases; the right side of the heart is then often able to make use of the heavily increased blood flow), but when the pulmonary arterial resistance is high, then an (additional) right ventricular assist device (RVAD) might be necessary to resolve the ...
While these side effects are not common (less than 10-20% of patients), many do report issues stemming from the placement and complication of the IVC while inside of the body. [20] 9% (12 of 132 patients) delayed filter penetration of the IVC greater than 3 mm; Parts of filter broke off in 2% (5 of 230 patients)
Flecainide is a medication used to prevent and treat abnormally fast heart rates. [1] This includes ventricular and supraventricular tachycardias. [1] Its use is only recommended in those with dangerous arrhythmias or when significant symptoms cannot be managed with other treatments. [1]
Levo-Transposition of the great arteries (also known as Levo-TGA, congenitally corrected TGA, double discordance, or ventricular inversion) is a rare, acyanotic heart defect in which the primary arteries are transposed, with the aorta anterior and to the left of the pulmonary artery, and the morphological left and right ventricles with their ...
In 1972 Bernard Lown, the inventor of the external defibrillator, and Paul Axelrod stated in the journal Circulation – "The very rare patient who has frequent bouts of ventricular fibrillation is best treated in a coronary care unit and is better served by an effective anti-arrhythmic program or surgical correction of inadequate coronary ...
Multiple system atrophy (MSA) is a rare neurodegenerative disorder [1] characterized by tremors, slow movement, muscle rigidity, postural instability (collectively known as parkinsonism), autonomic dysfunction and ataxia.
The search engine that helps you find exactly what you're looking for. Find the most relevant information, video, images, and answers from all across the Web.
Mavacamten was shown to reduce left ventricular outflow tract gradient (a measure of obstruction) and improve symptoms in patients with obstructive hypertrophic cardiomyopathy, and was approved for medical use in the United States in April 2022 [52] Aficamten, which has a shorter half life compared with mavacamten, achieves steady state within ...